{
    "SPADE_UN_18793": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_18793",
            "Peptide Name": "GLRC-5 (Synthetic AMPs, variant of GLR-19, Arg-rich; Leu-rich; 1S=S, UCSS1a)",
            "Source": "De novo designed, man-made sequences",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "GLRCRLGRLLRRLGRC",
            "Sequence Length": 16,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram-"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 1898.36,
            "PI": 12.0,
            "Hydrophobicity": -0.26,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Wang G, Watson KM, Mishra B, Lushnikova T, Buckheit RW Jr. 2011",
                    "Reference": "J AIDS Clinic Res S2:003. doi:10.4172/2155-6113.S2-003.Wang HIV screen project",
                    "Title": "De Novo Design of Antiviral and Antibacterial Peptides with \nVarying Loop Structures"
                }
            ],
            "Frequent Amino Acids": "RLG",
            "Absent Amino Acids": "ADEFHIKMNOPQSTUVWY",
            "Basic Residues": 6,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 5,
            "Polar Residues": 8,
            "Positive Residues": 6,
            "Negative Residues": 0,
            "Net Charge": 6,
            "Comments": "Sequence analysis: APD analysis reveals that this sequence is poorly similar (84.21%) toGLRC-2. R: 38%; L: 31%.Chemical modification:  one disulfide bond C4-C16.Activity: inhibited HSV-2MS in Vero cells (EC50 7.72 ug/ml); E. coli (MIC 30 uM); B. subtilis (MIC 60 uM).Toxicity: TC50 41.9 ug/ml in CEM-SS cells. UPdated 6/2024",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_12009",
                    "Similarity": 1.0,
                    "Sequence": "RTCGLRC"
                },
                {
                    "SPADE_ID": "SPADE_UN_18789",
                    "Similarity": 1.0,
                    "Sequence": "GLRCRLGRLLRRLGRCLLR"
                },
                {
                    "SPADE_ID": "SPADE_UN_18794",
                    "Similarity": 1.0,
                    "Sequence": "GLRCLRLRGRLRLGRCLLR"
                }
            ]
        }
    }
}